The SSPC mission is "to position Ireland as a global hub for process innovation and advanced manufacturing in the pharmaceutical industry". SSPC vision is to be "recognised as the leading centre of excelence shaping the future of global pharmaceuticals".
The SSPC transcends company and academic boundaries and is the largest research collaboration in Ireland, and one of the largest globally, within the pharmaceutical area. The SSPC supports over 300 active members, across academia and industry on a national and international basis.
The SSPC builds upon the success and foundations of the Solid State Pharmaceutical Cluster (2007-2013), which was funded by Science Foundation Ireland’s Strategic Research Cluster programme. The Solid State Pharmaceutical Cluster research programme focused exclusively upon the crystallisation stage of the manufacturing process. Within the pharmaceutical industry, this stage is the most challenging aspect of manufacturing, as there is a significant lack of fundamental understanding of the science and engineering challenges at this stage of the process.
SSPC 2013 Launch - €40 Millon Investment
Launched in July 2013, the Synthesis and Solid State Pharmaceutical Centre (SSPC), supporting 90 top-class researchers, is the largest research collaboration in Ireland, and one of the largest globally, within the pharmaceutical area. The SSPC represents a significant combined Science Foundation Ireland and industry investment of €42 million. Building upon the success of the Cluster (2007-2013), the SSPC research programme now spans the entire pharmaceutical production chain from synthesis of the molecule, to the isolation of the material, and the formulation of the medicine. In other words, the SSPC research programme focuses upon developing more environmentally sustainable methods for drug manufacturing; increasing the range of medicines available to the public; and reducing drug manufacturing costs.
The SSPC research programme aims to deliver relevant solutions that address the manufacturing needs of the pharmaceutical industry and in-turn lead next generation drug manufacture.
Global Brand Recognition
The success of the collaborative model earned SSPC global brand recognition both in academia and industry. This is evidenced by the fact that since the Cluster (2007-2013), in 2013, the SSPC extended its membership to 7 additional partners, another 5 in 2014 and a further 2 in 2017, industry partners and 12 international academic collaborators from North America, Europe and Asia. In 2014, the SSPC extended its membership to include 1 research performing institution. The scale of the centre has increased to over three fold its original size, and is now the largest research collaboration in Ireland, and one of the largest globally, within the pharmaceutical area. These partnerships afford SSPC access to complimentary expertise and infrastructure, and enhance SSPC’s opportunities to have impact not just in Ireland but globally. The SSPC continues to welcome new industry partners and academic partners from Ireland and globally.